Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
100.3 EUR | -0.10% | -0.30% | -8.28% |
20/06 | Zimmer Biomet Holdings, Inc. Appoints Devdatt Kurdikar to its Board of Directors | CI |
12/06 | Zimmer Biomet Enters Co-Marketing Deal With RevelAi Health | MT |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's enterprise value to sales, at 3.43 times its current sales, is high.
- The company is not the most generous with respect to shareholders' compensation.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.28% | 2.23TCr | - | ||
-5.60% | 18TCr | C+ | ||
-4.45% | 10TCr | C | ||
-4.15% | 6.75TCr | A | ||
-8.63% | 4.51TCr | B- | ||
+9.70% | 4.44TCr | B- | ||
+6.13% | 4.07TCr | B+ | ||
+15.22% | 2.98TCr | B | ||
+14.80% | 2.45TCr | A- | ||
-6.46% | 2.4TCr | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ZBH Stock
- ZIM Stock
- Ratings Zimmer Biomet Holdings, Inc.